Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2938 +0.0062 (+2.16%)

Streaming Delayed Price Updated: 11:43 AM EDT, Aug 10, 2026 Add to My Watchlist

Price and Volume

Volume	824,579
Open	0.2939
Bid (Size)	0.2920 (200)
Ask (Size)	0.2954 (800)
Prev. Close	0.2876
Today's Range	0.2802 - 0.3000
52wk Range	0.1980 - 5.140
Shares Outstanding	9,362,444
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 06, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

The Bull Lives Below $1: PRSO, ENSC, TNMG, QNME Stocks to Watch

August 04, 2026

Via AB Newswire

Performance

YTD	-56.7%	-56.7%
1 Month	+13.9%	+13.9%
3 Month	-56.4%	-56.4%
6 Month	-47.6%	-47.6%
1 Year	-89.7%	-89.7%

More News

These stocks are making the most noise in today's session. ↗

August 04, 2026

Via Chartmill

MissionIRNewsBreaks – SRX Global Inc. (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 04, 2026

Via Investor Brand Network

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026

From Vistagen Therapeutics, Inc.

Via GlobeNewswire

Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms ↗

June 15, 2026

Via Chartmill

Unusual volume stocks in Thursday's session ↗

July 02, 2026

Via Chartmill

Here are the top movers in Tuesday's session. ↗

June 30, 2026

Via Chartmill

Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗

June 30, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

June 30, 2026

Via Chartmill

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 30, 2026

From Vistagen

Via Business Wire

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026

From Vistagen

Via Business Wire

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 09, 2026

From Vistagen

Via Business Wire

Vistagen to Participate in Jefferies 2026 Global Healthcare Conference

May 27, 2026

From Vistagen

Via Business Wire

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026

From Vistagen

Via Business Wire

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 14, 2026

From Vistagen

Via Business Wire

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026

From Vistagen

Via Business Wire

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 08, 2026

From Vistagen

Via Business Wire

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

April 22, 2026

From Vistagen

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGN

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight

March 16, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

March 14, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGN

March 13, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026

March 12, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

March 12, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?

Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?

Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?

The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market

What is the current price of Vistagen Therapeutics, Inc. - Common Stock?

The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.2938

When was Vistagen Therapeutics, Inc. - Common Stock last traded?

The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 08/10/26 11:43 AM ET

What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?

The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 2.75M

How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?

Vistagen Therapeutics, Inc. - Common Stock has 3M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.